Share This Page

Want to share this page with a friend? Please provide the information below.
Fields with an asterisk (*) are required.

Send a copy to yourself



[Sender's name] thought you would be interested in learning about BANZEL® (rufinamide), an FDA-approved medication as an add-on treatment for seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults. BANZEL is available in 200-mg and 400-mg tablets and as an oral suspension supplied as an orange-flavored liquid containing 40 mg/mL of the medication.

Visit to learn more about the product, including full Prescribing Information and the Medication Guide.